



(51) International Patent Classification:

C07K 19/00 (2006.01) C12N 15/62 (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:

PCT/US2021/061410

(22) International Filing Date:

01 December 2021 (01.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/120,692 02 December 2020 (02.12.2020) US
63/153,666 25 February 2021 (25.02.2021) US
63/212,289 18 June 2021 (18.06.2021) US
17/476,661 16 September 2021 (16.09.2021) US

(71) Applicants: CELLULAR BIOMEDICINE GROUP HK

LIMITED [CN/CN]; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). CELLULAR BIOMEDICINE GROUP INC. [US/US]; 9605 Medical Center Drive, Suite 100, Rockville, MD 20850 (US).


(72) Inventors: YAO, Yihong; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). HUANG, Jiaqi; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN). YAO, Xin; Room 417, 4th Floor, Lippo Centre, Tower Two, No.89 Queensway, Admiralty, Hong Kong (CN).

(74) Agent: DAVITZ, Michael, A. et al.; Leason Ellis LLP, One Barker Avenue, Fifth Floor, White Plains, NY 10601 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: BCMA-TARGETED CHIMERIC ANTIGEN RECEPTORS



(57) Abstract: The present disclosure provides BCMA-targeted chimeric antigen receptors (CARs) as well as preparation methods and applications thereof. The CARs of the present disclosure targets BCMA-positive cells, and can be used for treating BCMA-positive B-cell lymphoma, multiple myeloma and plasma cell leukemia.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))